Evaluation of the efficacy of oxybutynin and imipramine in the management of detrusor instability

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN58226681

Enrollment

345

Registered

2000-10-25

Start date

1997-06-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Incontinence Urological and Genital Diseases Incontinence

Interventions

1. Oxybutynin: Oxybutynin titrated to a maximum dose of 5 mg tds and imipramin placebo 2. Imipramine: Imipramine titrated to a maximum dose of 75 mg bd and Oxybutynin placebo 3. Control: matching plac

Eligibility

Inclusion criteria

Inclusion criteria: 1. Failed conservative therapies for urinary dysfunction (nursing interventions) 2. Urodynamicaly proven detrusor instability

Exclusion criteria

Exclusion criteria: 1. Pregnancy 2. Malignancy 3. Fistula 4. Contra-indications to the use of oxybutynin or imipramine 5. Bladder outflow obstruction (measured urodynamically)

Design outcomes

Primary

Measure	Time frame
Clinical assessment using urinary diaries and 24 hour home pad tests.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026